FDA Sets Child Safety Rule After Death In Amgen Trial

Law360, New York (February 26, 2013, 5:03 PM EST) -- The U.S. Food and Drug Administration on Tuesday published a final rule strengthening safeguards for children enrolled in clinical trials on the same day it suspended pediatric trials of Amgen Inc.’s Sensipar following the death of a minor.

The agency halted all pediatric clinical trials of Amgen’s Sensipar, a drug used to treat a parathyroid condition, after a 14-year-old patient died during a study. The FDA said it was continuing to gather information on the incident and has not concluded whether or not Sensipar had a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.